Showing results (151-160 of 279) with videos related to

Sort By:
Pageof 28
JCO Precision Oncology|September 11, 2020
Prospective Clinical Validation of the InVisionFirst-Lung Circulating Tumor DNA Assay for Molecular Profiling of Patients With Advanced Nonsquamous Non-Small-Cell Lung CancerMichael A Pritchett, D Ross Camidge, Manu Patel, et al.
Plos One|December 19, 2013
Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancerKurtis D Davies, Sakshi Mahale, David P Astling, et al.
Frontiers in Oncology|July 30, 2025
Increased accrual of diverse patient populations in oncology phase I clinical trials at the University of Colorado Cancer CenterAhmed Alsafar, Sama L Kareem, Bradley R Corr, et al.
Cancer|April 16, 2013
Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patientsAndrew J Weickhardt, Robert C Doebele, W Thomas Purcell, et al.
Cancer Immunology Research|February 14, 2019
Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung CancerSha Zhao, Shengxiang Ren, Tao Jiang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2022
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung CancerRoy S Herbst, Margarita Majem, Fabrice Barlesi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2025
Development, Review, and Activation of Thoracic Oncology Investigator-Initiated TrialsDavid E Gerber, Claire R Wynters, Tanushree Prasad, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 6, 2021
Crizotinib in Patients With MET-Amplified NSCLCD Ross Camidge, Gregory A Otterson, Jeffrey W Clark, et al.
JAMA Network Open|July 15, 2025
Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non-Small Cell Lung Cancer: Update From the COAST Randomized Clinical TrialCharu Aggarwal, Alex Martinez-Marti, Margarita Majem, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2011
A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancerFred R Hirsch, Fairooz Kabbinavar, Tim Eisen, et al.
Pageof 28